Live Panel Schedule for Digital RESI September 2020

By Joey Wong, Investor Research Analyst, LSN

With only one week left, Digital RESI September 2020 is right around the corner! We are very excited to announce the live panel schedule for the conference.

All panels at Digital RESI September will be live-streamed. There will be two live panel sessions each day, starting as early as next week and will continue through the end of the conference, September 8-16. We welcome all Digital RESI September attendees to join and participate in these live sessions. Registered attendees can RSVP via the partnering platform to receive the dial-in information to join. For those who cannot make the live sessions, all the panel videos will be available via the virtual agenda.

It is worth noting that Global Investment and Partnership Panel, sponsored by Onelin Capital, is open to the public (no RESI registration required). Interested readers are welcome to RSVP here and participate in this panel.

Digital RESI September registrants will hear from the leading industry experts about their investment strategies and differentiated approaches, recent investments and areas of interest, and much more. If you haven’t already, register here for RESI September 2020 to participate in these live panels!

Below is the schedule for next week’s live panel sessions:

Corporate VC Panel – “The Corporate Landscape Morphed & New Opportunities Abound”

Date & Time: Tuesday, September 8, 10:00 – 10:50 am EST

Andy Merken (Moderator), Partner and Co-Chair, Life Sciences, Burns & Levinson
Lana Ghanem, Managing Director, Hikma Ventures
Mark Ralph, Executive Director, Boehringer Ingelheim Venture Fund
Tom Gibbs, Director, Debiopharm Innovation Fund

Medtech Strategics Panel – “Large Medical Device Firms Seeking External Innovation”

Date & Time: Tuesday, September 8, 12:00 – 12:50 pm EST

Geoff Dacosta (Moderator), Director of Business Development and Licensing, Medtronic
Christina Salys, Director of New Business development, Intuitive Surgical
David Uffer, Senior Partner, Alira Ventures
Rupert Winckler, Head of EMEA New Business Development, Olympus Corporation

Health System Partners Panel – “Care Providers and Payers Seek New Technologies”

Date & Time: Wednesday, September 9, 12:00 – 12:50 pm EST

Cyrll Philip, Principal, Providence Ventures
Linda Maxwell, Director, Biomedical Zone
Mayank Taneja, Director of Venture Investments, OSF Healthcare Ventures
Rajesh Aggarwal, Executive Vice President, Jefferson Strategic Ventures

Seed Funds Panel – “Investing in Emerging Science to Pursue High Rewards”

Date & Time: Wednesday, September 9, 2:00 – 2:50 pm EST

Gary Gershony (Moderator), Life Science Angels
Anya Roy, Head of Illumina Accelerator Cambridge, Illumina Accelerator
Jun Deng, Investment Partner, Joyance Partners
Nancy Kaufman, CEO, Beacon Capital
Prathna Ramesh, Executive Director, Maple Leaf Angels

Oncology Innovation Panel – “The Search for New Approaches to Diagnosing & Treating Cancer”

Date & Time: Thursday, September 10, 12:00 – 12:50 pm EST

Steve Yoder (Moderator), Vice President of Business Development, Taiho Oncology
Anthony Bajoras, Managing Director, Cancer Fund
Barbara Lavery, Chief Program Officer, Alliance for Cancer Gene Therapy
Duncan Young, Director of Search and Evaluation Oncology, Business Development & Licensing, AstraZeneca
Mark Krul, Partner, Aglala Oncology Fund

Global Investment and Partnership Panel – “Asia Firms Looking to Build Global Partnerships”

Date & Time: Thursday, September 10, 8:00 – 8:50 pm EST (Sponsored by Onelin Capital, Open to the public)

Judy Lee (Moderator), General Manager, Onelin Capital
Haolin Sung, Managing Partner, Chaperone Investment
Haruhiko Sugino, Director of Global Business Development, Otsuka Pharmaceuticals
Weiyong Sun, Senior Director of Specialty Medicine Search & Evaluation, Daichi Sankyo
Yao Li Ho, Senior Director of Business Development, LYFE Capital

Impact Investors Panel – “Life Science Investors Looking for More Than Financial Returns”

Date & Time: Friday, September 11, 12:00 – 12:50 pm EST

Lore Gruenbaum (Moderator), Vice President of Therapy Acceleration Program, Leukemia & Lymphoma Society
Chris Penland, Vice President of BioPharma Programs, Cystic Fibrosis Foundation
Kuldip Dave, Vice President of Research, ALS Association
Michael Cole, Founder and General Partner, Global Neurohealth Ventures
Paul Larkin, Manager of Research Innovation, Crohn’s and Colitis Foundation

Comments Leave a Comment
Categories Next Phase Archive, Redefining Early Stage Investments

Hot Mandates

Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease

The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need

The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
Hot Investor Mandate 3: Strategic Investment Firm of Large Pharma Invests in Early and Late Stage Therapeutics & Drug-Device Combinations, Especially Interested in Orphan and Rare Diseases

A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
Hot Investor Mandate 4: USA-Based Investment Firm Can Invest Over $10M in Innovative Medtech and Digital Health Companies Based in Texas or Southwestern USA

The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health

A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]

Featured: All About Innovation Challenge

Call for Innovation Challenge Applicants

Companies from all categories of life science are encouraged to apply to Innovation Challenge for RESI Healthtech Week. Eligible companies can apply to Day 1 the First Coast Innovator’s Gathering, Day 2 RESI Global Partnering or both. Applicants will have the opportunity for excellent visibility among investors and strategic partners.
RESI Healthtech Week Announces the First Coast Innovation Challenge on September 5th, And the RESI Global Innovation Challenge on September 6th

By Samuel Rubin, Business Development Manager, LSN For the first time this fall, Life Science Nation (LSN) will have two days of competition as part of the RESI Healthtech Week (September 5-7, 2018). Day 1 will feature the First Coast Innovation Challenge, where the top 10 ranked companies of the First Coast tech hubs will present […]
RESI Innovation Challenge: Meet The Asia-Based Startups That Took The Top Spots At RESI Boston Summer

By Jessica Yang, Investor Research Analyst, LSN On June 4th, more than 700 scientist-entrepreneurs and investors entered the exhibition hall at Boston Marriott Copley Place to participate in the RESI conference. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and digital health sectors. The 30 companies, evaluated by LSN’s expert […]
RESI Boston Summer Presents Innovation Challenge Finalists From Around The World

By James Huang, Research Analyst, LSN We are excited to showcase the top RESI Innovation Challenge startup applicants, who will be taking part in the poster presentation showcase at the second annual RESI BIO held in Boston this year, alongside the BIO International conference. These handpicked companies represent the key sectors of the healthcare space […]
How to Use the RESI Innovation Challenge to Build Success for Your Company: An Interview with RESI Winner Steven ten Holder (Acorn Biolabs)

An interview with Steven ten Holder, COO, Acorn Biolabs – By Greg Mannix, VP of International Business Development, LSN This year’s 2nd place finisher at the Innovation Challenge at RESI on MaRS was Acorn Biolabs. LSN interviewed COO, Steven ten Holder and got some key takeaways on how Acorn used the RESI Innovation Challenge effectively: […]

Search

Live Panel Schedule for Digital RESI September 2020

Leave a Reply Cancel reply

Popular Topics

Hot Mandates

Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease

Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need

Hot Investor Mandate 3: Strategic Investment Firm of Large Pharma Invests in Early and Late Stage Therapeutics & Drug-Device Combinations, Especially Interested in Orphan and Rare Diseases

Hot Investor Mandate 4: USA-Based Investment Firm Can Invest Over $10M in Innovative Medtech and Digital Health Companies Based in Texas or Southwestern USA

Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health

Featured: All About Innovation Challenge

Call for Innovation Challenge Applicants

RESI Healthtech Week Announces the First Coast Innovation Challenge on September 5th, And the RESI Global Innovation Challenge on September 6th

RESI Innovation Challenge: Meet The Asia-Based Startups That Took The Top Spots At RESI Boston Summer

RESI Boston Summer Presents Innovation Challenge Finalists From Around The World

How to Use the RESI Innovation Challenge to Build Success for Your Company: An Interview with RESI Winner Steven ten Holder (Acorn Biolabs)

LSN Twitter

Contact us

Archives

Subscribe

Life Science Nation

RESI Conference Series

Investor Platform Demo

Company Platform Demo

Follow Us

Learn More

Site Map

Search

Share this:

Like this:

Related

Leave a Reply Cancel reply

Popular Topics

Hot Mandates

Featured: All About Innovation Challenge

Contact us

Archives

Subscribe

Life Science Nation

RESI Conference Series

Investor Platform Demo

Company Platform Demo

Follow Us

Learn More

Site Map